ClinicalTrials.gg
Enrolling by invitationNCT07494188Updated Mar 27, 2026

Sleep Screening and Intervention for Adolescents With Type 1 Diabetes in a Clinical Diabetes Center

An interventional study of Sleep intervention in Type 1 Diabetes, sponsored by University of Colorado, Denver. Enrolling by invitation at 1 site in United States. Open to participants aged 11 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
11 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver — 10 open to participants now, 13 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · University of Colorado, Denver.

Planned enrollment
18th of 44
50 · median 44
Started
2026
with 2 others
No phase
25 of 58
6 open now
Primary completion
2026-12
later than 4 of 12 live
Registered
57th of 58
by date

Among the 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver, this one is the 18th largest by planned enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2026, is one of 25 with no phase, reaches primary completion later than 4 of the 12 other live ones, and was the 57th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

10 of the 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 11 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver, or all of them as a file.
02

Study summary

This study is evaluating an in-clinic sleep screening and intervention algorithm for youth with type 1 diabetes. This study will assess health care provider feasibility of completion of intervention and long term follow up for adolescents with T1D.

Read the detailed description

This study involves enrollment of adolescents with T1D in conjunction with a diabetes health care provider at the Barbara Davis Center. Adolescents will complete a sleep screening questionnaire prior to the clinic visit. If the adolescent screens positive for sleep concerns, they will complete an indepth questionnaire to identify the barriers to sleep and this information will be provided to the health care provider. During the routine T1D clinic visit, the health care provider will be provided with the questionnaire answers and sleep interventions, and will address these at their discretion throughout the clinical encounter. Adolescents enrolled in the study will be follow at 3 months. For those that screened positive for sleep concerns, questionnaires will be completed related to the intervention to determine completion, retention, and follow through. Those who did not screen positive, will additionally complete a follow up sleep screener to assess consistency in their sleep health.

03

Conditions studied

  • Type 1 Diabetes

Keywords

  • Type 1 diabetes
  • Adolescents
  • Sleep health
04

Who can participate

Ages eligible
11 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 diabetes
  • Receiving care at the Barbara Davis Center
  • Using a continuous glucose monitor

Exclusion criteria

Exclusion Criteria:

  • Undiagnosed or untreated sleep disorder
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Sleep Intervention

    All adolescents enrolled will complete the sleep screening questionnaire

    Behavioral: Sleep intervention

Interventions

  • BehavioralSleep intervention

    Adolescents that screen positive for sleep concerns will receive targeted interventions based on their self-reported sleep barriers. These will be provided by the health care provider.

06

What researchers measure

Primary outcomes

  1. Intervention Completion Rate

    Assess the feasibility/rate of completion of sleep intervention discussion within the clinic session based on the percent of interventions completed for those who screened positive in the sleep screening.

    Time frame: Day 1

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — Data sharing can be made available upon request on a case by case basis

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 9 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 27, 2026
StartActual
Feb 23, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07494188
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Feb 23, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Mar 27, 2026

Study contacts

Erin Cobry, MD
principal investigator · University Of Colorado, Barbara Davis Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion